A compound represented by the following general formula (I):
[wherein R1 represents hydrogen atom or a C16 alkyl group, A and B represent -(CH2)2-, -(CH2)3- or -(CH2)4-, X represents -N(R2)- (R2 represents hydrogen atom or a C1-6 alkyl group), -CO-, -C(=N-R3)- (R3 represents hydrogen atom or a C1-6 alkyl group), or - C(=C(R4)(R5))- (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.
A compound represented by the following general formula (I):
[wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3— or —(CH2)4—, X represents —N(R2)— (R2 represents hydrogen atom or a C1-6 alkyl group), —CO—, —C(═N—R3)— (R3 represents hydrogen atom or a C1-6 alkyl group), or —C(═C(R4)(R5))— (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.
Many synthetic retinoids contain an aromatic structure with a bulky hydrophobic fragment. In order to obtain retinoids with therapeutic potential that do not bind to or activate retinoic acid X receptors (RXRs), we focused on the introduction of novel hydrophobic moieties, that is, metacyclophane, phenalene and benzoheptalene derivatives. The designed compounds were synthesized and their agonistic